I operate at the intersection of AI, human genetics, and commercial strategy. At Genomics, I help pharmaceutical and biotech organizations bring large-scale human genetics into earlier, more confident R&D decision-making—through a combination of advanced analytics, AI-enabled tooling, and strategic consulting support.

My work centers on partnering with senior R&D, statistical genetics, and strategy leaders to operationalize genetics across the pipeline: accelerating target discovery, strengthening validation, improving translational confidence, and identifying patient populations more likely to respond to therapy.

Over the past 20 years, I’ve:

•	Built, led, and mentored high-performing sales teams in AI and SaaS.
•	Managed global accounts and developed go-to-market strategies that drive adoption.
•	Closed multi-million-dollar enterprise engagements and partnerships across R&D industries 
•	Negotiated strategic agreements that expand revenue and accelerate growth.

I’m also the author of Mastering AI Sales: Essential Knowledge for B2B Professionals, a practical playbook that equips founders, consultants, and sales leaders with frameworks to win complex AI sales.
👆 Now available – click the link in my profile header to get your copy.

Specialties

•	AI-Enabled Human Genetics / Genomics Commercial Strategy
•	Building & Scaling Sales Teams
•	Enterprise AI Sales & Stakeholder Management
•	Go-to-Market Strategy (Consulting + Product Hybrid Models)
•	Strategic Partnerships & Revenue Expansion
•	Cross-Functional Leadership & Commercial Alignment

Let’s connect if you’re scaling AI solutions, leading enterprise transformations, or looking to accelerate sales impact in complex markets.

David Walker

Early JPM takeaways…

• Causal genetics is firmly front and center, increasingly used to de-risk target identification and validate programs earlier in development.
• Patient stratification is no longer optional. Leaders are entering the clinic with greater emphasis on clear responder hypotheses and stronger supporting evidence.
• AI is maturing quickly. Fewer proof-of-concept discussions, more concrete examples of measurable impact across R&D.
• Funding sentiment appears cautiously improved, particularly for companies with differentiated science and disciplined, evidence-led strategies.

The Genomics leadership team is here all week and we’d be happy to connect and compare notes.

#jpm2026 #Genomics

VP of Client Service | Leading Enterprise AI Partnerships | Team Builder | Author of Mastering AI Sales | MBA, MSc.

JPM was an outstanding experience. The energy, quality of conversations, and level of innovation throughout the week were exceptional.

We were delighted to host a Genomics reception, where we shared how Mystra, our AI enabled platform, enables teams to apply human genetics more effectively to R&D decision-making. The depth of engagement reinforced just how central genetics has become to smarter target selection and clinical decisions.

A few key takeaways stood out for me…

1. Platforms must change decisions
AI creates value only when it changes decisions e.g. which targets advance, which programs stop earlier, and which patients enter trials. The strongest platforms enable fewer, higher-confidence bets.

2. Data advantage ≠ more data
The ultimate advantage is signal, not scale. Rare disease cohorts, longitudinal datasets, and multi-omics data with clinical context enable better questions to be asked and reduce false confidence.

3. Causal genetics is becoming foundational
Human genetics is increasingly being used to improve probability of success, de-risk programs earlier, enable patient stratification, and support smarter trial design.

The next phase of R&D won’t be defined by who moves fastest, but by who makes the best decisions earliest, using well-curated data, causal evidence, and AI together.

#JPM26 #Genetics #TargetValidation #PatientStratification #DrugDevelopment

I am looking forward to participating in the 25th Precision Medicine World Conference (PMWC 2026), taking place March 4–6, at the Santa Clara Convention Center in California, co-hosted by Stanford, UCSF & Yale.

Meet me at #PMWC26, March 4-6, where over 400 speakers, including Nobel Laureates Mary Brunkow and W.E. Moerner, OpenAI's President & Co-Founder, FDA Commissioner (Fmr), Judy Faulkner (Epic), Carl June (UPenn), David Sinclair (Harvard) & more will gather to help advance precision medicine & AI.

Speakers: www.PMWCintl.com/Speakers
Program: www.PMWCintl.com/Program

Register for PMWC 2026 to save using my personal code: https://lnkd.in/e9MQeSUr

 PMWC - Precision Medicine World Conference
#PMWC26 #PMWC2026 #PrecisionMedicine #Biotech

Open article: PMWC 2026 Registration, Tickets & Pricing by pmwcintl.com

PMWC 2026 Registration, Tickets & Pricing

Great to see the Genomics team out in force at #FOG2026 
If you’re at FOG, make sure you stop by by Booth #77 to say hello and check out the Mystra D&D Quest, a fun, hands-on way to experience how we support drug target discovery and development through human genetics and multi-omics.   Plus Dirk Paul, Head of Development, talking about: “The Genome and Beyond: Advancing Drug Discovery and Development” Today 12:00–12:30 | Multi-Omics Stage
Have a great show, team 👋
#DrugDiscovery #MultiOmics #Genomics #DrugDevelopment #FOG2026 #FrontLineGenomics

Day 1 at #FOG2026 is here 🚀 

You can find us at Booth #77 - come say hello to the team and try our iconic Mystra D&D Quest 🧙 - an interactive challenge that gives you a hands-on experience with our drug target discovery and development platform! 

🎤 Today | 12:00 - 12:30 | Multi-Omics stage
Join Dirk Paul, Head of Development, for "The Genome and Beyond: Advancing Drug Discovery and Development"
What to expect:
💡 Insights into Genomics' genotype-phenotype platform & analytical pipelines
🧬  A deep dive into how multi-omics integration drives target identification & data-driven patient stratification
🌍  Real-world case case studies showcasing risk prediction and pharmacomimetic approaches in action

See you on the floor 👋 

#drugdiscovery #MultiOmics #Genomics #DrugDevelopment Front Line Genomics

amino

As a Client Partner I led the management and revenue growth of the Master Services Agreement (MSA) with AstraZeneca, ensuring seamless execution of high-value digital transformation initiatives while expanding scope and driving multi-million-dollar service engagements

As Director, I was dedicated to advancing innovation in life sciences R&D through strategic collaboration and partnerships with AwS, Snowflake, Databricks and the Pistoia Alliance. I previously served as a Partner at Amino, where I guided organisations in digital transformation, information architecture, master data management, and information governance. Specialising in scaling advanced analytics and AI, I worked to establish a robust data foundation for impactful research outcomes.

By aligning technologies with unique strategic priorities, I accelerated the integration of AI, Real-World Data (RWD), and Real-World Evidence (RWE) into life sciences R&D. My focus on information architecture, master data management, and information governance principles ensured that data remained FAIR at scale.

In the evolving data and AI landscape, life sciences R&D presents a distinctive opportunity for insights. While at Amino, I helped address challenges related to legacy systems, processes, and data quality, championing pragmatic and effective solutions in shaping information architecture, master data management, and information governance strategies to ensure FAIR data.

Navigating these complexities, I worked closely with life sciences R&D teams at Bayer, Novo Nordisk, AstraZeneca, Novartis and Eli Lilly to operationalise advanced analytics and AI, ensuring a strong information governance and data strategy. Amino, known for its excellence in the field, provided solutions to build a strong data foundation for transformative outcomes.

EMEA Business Development Director I Life Sciences I IT Professional Services I Data & AI 

Globant

At Globant’s Healthcare & Life Sciences Studio, I helped reinvent the life sciences ecosystem by developing technology-driven solutions that accelerate innovation, improve patient outcomes, and enhance operational efficiency.  

I managed a P&L exceeding $30M and led 30 high-performing professionals. 

My work bridged the gap between life sciences and technology, enabling organisations to leverage AI, digital capabilities, and data platforms to drive measurable impact.

Managing Partner | Life Sciences | IT Professional Services & Software Product Development

SparkBeyond

As EMEA Lead for Healthcare & Life Sciences I established partnerships globally with multi-national pharmaceutical and life science organisations, overseeing engagements across market access, pharmacovigilance & clinical research and development. My role encompassed solution portfolio design, planning, design, implementation, marketing, people management, project management, commercial strategy and developing vision.

Fluent in both data science and business, I bridge the gap between AI innovation, and commercial execution. I have built enterprise-scale data ecosystems with cloud hyperscalers (AWS, Google Cloud, Microsoft Azure), data platforms (Databricks, Snowflake, SAP), and enterprise integration solutions to help organizations scale AI and Data Science capabilities with speed and precision.

I shaped AI & Data Science strategies with budgets exceeding $2M per engagement for SparkBeyond.

EMEA Lead I Healthcare & Life Sciences I SaaS & Data Science IT Professional Services 

DXC Technology

At DXC Technology, I led the Healthcare & Life Sciences Analytics practice within the UKIIMEA organization, driving digital transformation through AI, machine learning, and advanced analytics solutions. I provided strategic advisory and thought leadership to clients and partners, shaping data-driven strategies that delivered measurable business outcomes.

I successfully managed a P&L with consistent 40% margins, overseeing a portfolio of high-value analytics and digital product engagements. My role encompassed business development, pre-sales, strategy, and solution delivery—shaping multi-million-dollar initiatives, securing deals up to $30M, and scaling AI and big data solutions across healthcare and life sciences.

From concept to execution, I led the development of analytics-driven solutions, driving innovation in information management, business intelligence, and AI-powered digital products to accelerate insights and impact."

Practice Lead I Healthcare and Life Sciences I Advanced Analytics & AI Professional Services 

Qlik

At Qlik, a leading SaaS company in business intelligence and data visualisation, I drove revenue growth in the healthcare and life sciences market. Over my tenure, I took on increasing quota responsibility, consistently achieving and exceeding targets while expanding our customer acquisition and professional services footprint. In addition to revenue growth, which I scaled from $5M to $20M I also took on leadership responsibilities, managing a team of three and contributing to the development of talent within the organisation.

Specialising in consultative selling, strategic account growth, and professional services expansion, I helped organisations from small medium sized businesses, to mid-market to enterprise to key accounts, turn complex data into actionable insights, supporting their digital transformation journeys.

A proven leader in business development, client success, and team leadership, I thrive on delivering measurable impact, scaling revenue, and fostering high-performing teams in fast-paced, SaaS-driven environments.

Business Development Director I Healthcare & Life Sciences I EMEA I SaaS & IT Professional Services 

Dynamic and strategic sales business leader specialising in Data & AI-driven digital transformation, business development, and advanced data solutions. Proven track record of generating profitable revenue, driving commercial growth, and delivering multi-million-dollar results across life sciences, biotech, CRO, and healthcare sectors.

Adept at developing AI-focused strategies, establishing high-value partnerships, and building data ecosystems with cloud service providers (AWS, Google Cloud, Microsoft Azure), data platforms (Databricks, Snowflake, SAP), and enterprise integration solutions. Extensive experience collaborating with global systems integrators and independent software vendors, leading cross-functional, globally matrixed teams to achieve transformational results.

Familiar with data science and machine learning platforms such as Kubeflow, AWS SageMaker, Google Vertex AI, and Azure Machine Learning, as well as programming languages like Python and R, to effectively scope and deliver AI and advanced analytics projects. Experienced in bridging technical and commercial teams, ensuring alignment between business strategy, data capabilities, and operational execution.

Beyond R&D and commercial applications, I have worked across Chemical Manufacturing and Controls (CMC), with a strong understanding of Good Manufacturing Practice (GMP) and the broader manufacturing and supply chain landscape. This expertise enables me to support services companies targeting digital transformation in manufacturing, automation, and AI-driven supply chain optimisation.

Known for combining scientific and commercial acumen, I translate complex data and AI strategies into measurable business impact. In recent years, I’ve worked with leading life sciences organisations—including AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Pfizer, Novartis, and Novo Nordisk—driving digital transformation and innovation through professional services, software engineering, and IT consulting.

My experience spans the entire value chain, from pre-clinical research to product launch, delivering bespoke technology solutions tailored to each stage. Beyond pharma and biotech, I have led engagements within SaaS, software development, and IT professional services, including my time at Qlik, where I built scalable AI and analytics solutions.

This deep experience provides insight into how systems integrators, digital consultancies, and innovation firms can partner with life sciences organisations to leverage data, AI, cloud, manufacturing, and supply chain technologies for competitive advantage.

taplio

The Battle

David Walker

Kyle Bradley

Followers

Posts

Engagements

Likes

Performance ScoreDavid Walker's LinkedIn Performance

Ready to grow your LinkedIn presence?

taplio

The Battle

David Walker

Kyle Bradley

Followers

Posts

Engagements

Likes

Performance Score.css-goub6s{font-size:var(--chakra-fontSizes-md);font-weight:500;color:var(--chakra-colors-gray-600);display:block;margin-top:var(--chakra-space-1);}David Walker's LinkedIn Performance

Ready to grow your LinkedIn presence?

Performance ScoreDavid Walker's LinkedIn Performance